Developing medical countermeasures to protect civilians against intentional and accidental toxic chemical exposure that can lead to mass casualties is a major goal of the biodefense program at NIH. More specifically, this goal is executed by the Chemical Countermeasures Research Program (CCRP) at NIAID in partnership with several other ICs across the NIH (NIH Strategic Plan and Research Agenda for Medical Countermeasures Against Chemical Threats). NIAMS has been a critical and active partner in this trans-NIH effort since the CCRP’s inception in 2006. In order to broaden its research base and raise the awareness of the scientific community at large about the urgent need for effective countermeasures against chemical threats, the CCRP is encouraging its IC partners to issue IC-specific FOAs to further engage their respective research disciplines that are not currently engaged in the medical countermeasure research field. This initiative is a response to that request. The intent of the initiative is to encourage the NIAMS skin research community to contribute to the basic understanding of injuries caused by those toxic chemicals identified by the U.S. Department of Homeland Security as high consequence public health threats and to explore the local and systemic mechanisms of chemical wound development, healing, and long-term consequences.
Current CounterACT FOAs
- PAR-19-039: Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (U01 Clinical Trial Not Allowed)
- PAR-19-040: Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01 Clinical Trial Optional)
- PAR-20-316: NIH Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 - Clinical Trial Optional)
- PAR-20-253: Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects (R21 Clinical Trial Not Allowed)
- PAR-21-209: NIH Countermeasures Against Chemical Threats (CounterACT) Early-stage Investigator Research Award (R21 Clinical Trial Not Allowed)